Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

TABRECTA

CAPMATINIB HYDROCHLORIDE

Standard Dose
EQ 150MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview TABRECTA is listed in Drugs@FDA under application 213591 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient CAPMATINIB HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 150MG BASE Sponsor NOVARTIS PHARM Submission history Latest submission status date: 2024-03-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview TABRECTA is listed in Drugs@FDA under application 213591 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient CAPMATINIB HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 150MG BASE Sponsor NOVARTIS PHARM Submission history Latest submission status date: 2024-03-14 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.